- Advertisement -
Home Coronavirus The Paycheck Protection Program and Health Care Enhancement Act: Summary of Key...

The Paycheck Protection Program and Health Care Enhancement Act: Summary of Key Health Provisions

- Advertisement -
Office of the Secretary COVID-19 Testing: For an additional amount for “Public Health and Social Services Emergency Fund” to prevent, prepare for, and respond to coronavirus, domestically or internationally, for necessary expenses to research, develop, validate, manufacture, purchase, administer, and expand capacity for COVID-19 tests to effectively monitor and suppress COVID-19, including tests for both active infection and prior exposure, including molecular, antigen, and serological tests, the manufacturing, procurement and distribution of tests, testing equipment and testing supplies, including personal protective equipment needed for administering tests, the development and validation of rapid, molecular point-of-care tests, and other tests, support for workforce, epidemiology, to scale up academic, commercial, public health, and hospital laboratories, to conduct surveillance and contact tracing, support development of COVID-19 testing plans, and other related activities related to COVID-19 testing.

Of the funds provided:

  • States, Localities, Territories, and Certain Others: Not less than $11,000,000,000 shall be for States, localities, territories, tribes, tribal organizations, urban Indian health organizations, or health service providers to tribes for necessary expenses to develop, purchase, administer, process, and analyze COVID-19 tests, including support for workforce, epidemiology, use by employers or in other settings, scale up of testing by public health, academic, commercial, and hospital laboratories, and community-based testing sites, health care facilities, and other entities engaged in COVID-19 testing, conduct surveillance, trace contacts, and other related activities related to COVID-19 testing.
    • Of this:
      • not less than $2,000,000,000 shall be allocated to States, localities, and territories according to the formula that applied to the Public Health Emergency Preparedness cooperative agreement in fiscal year 2019,
      • not less than $4,250,000,000 shall be allocated to States, localities, and territories according to a formula methodology that is based on relative number of cases of COVID-19, and
      • not less than $750,000,000 shall be allocated in coordination with the Director of the Indian Health Service, to tribes, tribal organizations, urban Indian health organizations, or health service providers to tribes.
    • The HHS Secretary shall submit such formula methodology to the Committees on Appropriations of the House of Representatives and the Senate one day prior to awarding such funds.
    • The HHS Secretary may satisfy these funding thresholds by making awards through other grant or cooperative agreement mechanisms.
    • Not later than 30 days after the date of enactment of this Act, the Governor or designee of each State, locality, territory, tribe, or tribal organization receiving funds pursuant to this Act shall submit to the HHS Secretary its plan for COVID-19 testing, including goals for the remainder of calendar year 2020, to include:
      • (1) the number of tests needed, month-by-month, to include diagnostic, serological, and other tests, as appropriate;
      • (2) month-by-month estimates of laboratory and testing capacity, including related to workforce, equipment and supplies, and available tests; and
      • (3) a description of how the State, locality, territory, tribe, or tribal organization will use its resources for testing, including as it relates to easing any COVID-19 community mitigation policies.
    • Funds shall be allocated within 30 days of the date of enactment of this Act.
  • CDC: Not less than $1,000,000,000 shall be transferred to the “Centers for Disease Control and Prevention — CDC-Wide Activities and Program Support” for surveillance, epidemiology, laboratory capacity expansion, contact tracing, public health data surveillance and analytics infrastructure modernization, disseminating information about testing, and workforce support necessary to expand and improve COVID-19 testing.
  • NIH/NCI: Not less than $306,000,000 shall be transferred to the “National Institutes of Health — National Cancer Institute” to develop, validate, improve, and implement serological testing and associated technologies for the purposes specified under this paragraph in this Act.
  • NIH/NIBIB: Not less than $500,000,000 shall be transferred to the “National Institutes of Health — National Institute of Biomedical Imaging and Bioengineering” to accelerate research, development, and implementation of point of care and other rapid testing related to coronavirus.
  • NIH/Office of the Director: Not less than $1,000,000,000 shall be transferred to the “National Institutes of Health — Office of the Director” to develop, validate, improve, and implement testing and associated technologies; to accelerate research, development, and implementation of point of care and other rapid testing; and for partnerships with governmental and non-governmental entities to research, develop, and implement the activities outlined in this proviso. These funds may be transferred to the accounts of the Institutes and Centers of the NIH for these purposes; this transfer authority is in addition to all other transfer authority available to the NIH.
  • BARDA: Not less than $1,000,000,000 shall be available to the Biomedical Advanced Research and Development Authority for necessary expenses of advanced research, development, manufacturing, production, and purchase of diagnostic, serologic, or other COVID-19 tests or related supplies, and other activities related to COVID-19 testing at the discretion of the Secretary.
  • FDA: $22,000,000 shall be transferred to the “Department of Health and Human Services — Food and Drug Administration–Salaries and Expenses” to support activities associated with diagnostic, serological, antigen, and other tests, and related administrative activities.
  • Funds may be used for:
    • grants for the rent, lease, purchase, acquisition, construction, alteration, renovation, or equipping of non-federally owned facilities to improve preparedness and response capability at the State and local level for diagnostic, serologic, or other COVID-19 tests, or related supplies.
    • construction, alteration, renovation, or equipping of non-federally owned facilities for the production of diagnostic, serologic, or other COVID-19 tests, or related supplies, where the HHS Secretary determines that such a contract is necessary to secure, or for the production of, sufficient amounts of such tests or related supplies.
    • purchase of medical supplies and equipment, including personal protective equipment and testing supplies to be used for administering tests, increased workforce and trainings, emergency operation centers, and surge capacity for diagnostic, serologic, or other COVID-19 tests, or related supplies.
  • Products purchased with these funds may, at the discretion of the HHS Secretary, be deposited in the Strategic National Stockpile.
  • HRSA: $600,000,000 shall be transferred to “Health Resources and Services Administration–Primary Health Care” for grants under the Health Centers program and for grants to federally qualified health centers.
    • Certain requirements regarding consideration of applications providing care to those medically underserved in rural vs. urban areas and distribution of grants under the Public Health Service Act shall not apply to these funds.
  • Rural Health Clinics: $225,000,000 shall be used to provide additional funding for COVID-19 testing and related expenses, through grants or other mechanisms, to rural health clinics as defined in section 1861(aa)(2) of the Social Security Act, with such funds also available to such entities for building or construction of temporary structures, leasing of properties, and retrofitting facilities as necessary to support COVID-19 testing.
    • Such funds shall be distributed using the procedures developed for the CARES Act Provider Relief Fund; may be distributed using contracts or agreements established for such program; and shall be subject to the process requirements applicable to such program.
    • The HHS Secretary may specify a minimum amount for each eligible entity accepting such assistance.
  • Up to $1,000,000,000 may be used to cover the cost of testing for the uninsured, using the definitions applicable to funds provided under this heading in Public Law 116-127.
  • Not later than 21 days after the date of enactment of this Act, the HHS Secretary, in coordination with other appropriate departments and agencies, shall issue a report on COVID-19 testing. Such report shall:
    • include data on demographic characteristics, including, in a de-identified and disaggregated manner, race, ethnicity, age, sex, geographic region and other relevant factors of individuals tested for or diagnosed with COVID-19, to the extent such information is available.
    • include information on the number and rates of cases, hospitalizations, and deaths as a result of COVID-19.
    • be submitted to the Committees on Appropriations of the House and Senate, and the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate, and updated and resubmitted to such Committees, as necessary, every 30 days until the end of the COVID-19 public health emergency first declared by the HHS Secretary on January 31, 2020.
  • Not later than 180 days after the date of enactment of this Act, the HHS Secretary shall issue a report on the number of positive diagnoses, hospitalizations, and deaths as a result of COVID-19, disaggregated nationally by race, ethnicity, age, sex, geographic region, and other relevant factors. Such report shall include epidemiological analysis of such data.
  • Not later than 30 days after the date of the enactment of this Act, the HHS Secretary, in coordination with other departments and agencies, as appropriate, shall report to the Committees on Appropriations of the House and Senate, the Committee on Energy and Commerce of the House of Representatives, and the Committee on Health, Education, Labor, and Pensions of the Senate on a COVID-19 strategic testing plan. Such plan shall:
    • assist States, localities, territories, tribes, tribal organizations, and urban Indian health organizations, in understanding COVID-19 testing for both active infection and prior exposure, including hospital-based testing, high-complexity laboratory testing, point-of-care testing, mobile-testing units, testing for employers and other settings, and other tests as necessary.
    • include estimates of testing production that account for new and emerging technologies, as well as guidelines for testing.
    • address how the HHS Secretary will increase domestic testing capacity, including testing supplies; and address disparities in all communities.
    • outline Federal resources that are available to support the testing plans of each State, locality, territory, tribe, tribal organization, and urban Indian health organization.
    • be updated every 90 days until funds are expended.
Public Health and Social Services Emergency Fund

(including transfer of funds)

 

$25,000,000,000 To remain available until expended
- Advertisement -
- Advertisement -

Stay Connected

16,985FansLike
2,458FollowersFollow
61,453SubscribersSubscribe

Must Read

- Advertisement -

US investigates second suspected case of mystery ‘syndrome’ near White House

The intelligence community still isn't sure who is causing the strange array of nervous system symptoms, or if they can be definitively termed "attacks."...

One of America’s largest hospital chains, Community Health Systems, has been suing patients during the pandemic

But even as Bull was helping send patients to Moberly Regional, the hospital was in the process of suing her and at least one...

Related News

US investigates second suspected case of mystery ‘syndrome’ near White House

The intelligence community still isn't sure who is causing the strange array of nervous system symptoms, or if they can be definitively termed "attacks."...

One of America’s largest hospital chains, Community Health Systems, has been suing patients during the pandemic

But even as Bull was helping send patients to Moberly Regional, the hospital was in the process of suing her and at least one...

The stark global divide in the Covid-19 pandemic

Bodies arrive at a mass cremation site in New Delhi on April 23. A second wave of Covid-19 has been devastating India. (Atul Loke/The...
- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here